Press Releases
Sep. 21, 2017 biOasis Announces Voting Results for 2017 Annual Meeting
The Company welcomes new board members Dr. Nancy Stagliano, Dr. Deborah Rathjen and Dr. Maha Radhakrishnan
Sep. 18, 2017 biOasis Announces Rob Hutchison, Founder, to Retire as Chairman & Board Member
Additional Board & Leadership Team Changes Also Announced
Sep. 7, 2017 biOasis Announces Formation of Scientific Advisory Board to Advance the Science for the Company’s Blood-Brain Barrier Drug Delivery Platform
Distinguished Research & Development Scientists Prof. John H. Krystal, M.D., Jeffrey L. Cummings, M.D. and John P. Wikswo, Jr., Ph.D. Appointed as Inaugural Members World-renowned Psychiatrist Dr. Krystal will Serve as Chair of the SAB
Aug. 28, 2017 biOasis Announces Nominees to the Board of Directors, Chairman Transition and Details of its Annual General Meeting of Shareholders
New Board nominees include accomplished biopharmaceutical executives Nancy Stagliano, Ph.D., CEO at True North Therapeutics; Deborah Rathjen, Ph.D., CEO & Managing Director of Bionomics; and Maha Radhakrishnan, M.D., SVP & Head of World Wide Medical at Bioverativ Therapeutics Inc. biOasis Founder Mr. Rob Hutchison will step down as Chairman of the Board on Dec. 31, 2017
Aug. 21, 2017 biOasis Appoints Doug Williams, MBA, Executive Vice President, Chief Business Officer
Williams bring significant experience in working with both large, multinational pharmaceutical companies & start-up biotechnology alliances
Jun. 26, 2017 biOasis Appoints Catherine London, Executive Vice President, Head of Corporate Communications and Investor Relations
VANCOUVER, BC–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI) welcomes Catherine London as executive vice president, head of corporate communications and investor relations, effective immediately. London will report to Dr. Mark Day, president and chief executive officer of biOasis. In this newly created position, London will have responsibility for leading all external communications, corporate visibility, brand-building,… Read more »
Jun. 15, 2017 biOasis Engages FreeMind Group to Access Non-Dilutive Global Funding Opportunities
VANCOUVER, BC–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI) announced today it has engaged FreeMind Group to assist the Company pursue non-dilutive funding opportunities globally. The biOasis Transcend technology has been demonstrated to transport several different drug modalities (e.g., antibodies, enzymes, small molecules) across the blood-brain barrier (BBB) and into the central nervous system (CNS). The… Read more »
Jun. 14, 2017 biOasis CEO Dr. Mark Day Releases Details of Corporate Plans in Message to Shareholders
VANCOUVER, BC–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI) Dr. Mark Day, chief executive officer, has issued a message to shareholders detailing plans for the advancement of the Transcend Platform and the company’s in-house programs. To the Shareholders of biOasis Technologies Inc.: As the new CEO of biOasis, I am delighted to send my first message… Read more »
Jun. 8, 2017 biOasis to Present at The Global Chinese Financial Forum – Shanghai Conference 2017
VANCOUVER, BC–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI) announced today that Dr. Mark Day, the chief executive officer of biOasis, will present at the Global Chinese Financial Forum (GCFF) – Shanghai Conference 2017, in Shanghai, China, on June 22, 2017. biOasis Board Chairman, Rob Hutchison, will attend the conference with Dr. Day. Dr. Day’s presentation,… Read more »
Jun. 4, 2017 biOasis to Present at the 16th International Postgraduate Course on Lysosomal Storage Disorders
VANCOUVER, BC–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI) announced today that Dr. Mark Day, chief executive officer, will present at the 16th International Postgraduate Course on Lysosomal Storage Disorders, in Nierstein (Mainz), Germany on June 07–10, 2017. Dr. Day’s presentation, “Improving the Probability of Success in CNS Drug Discovery and Development: A Case Study,” targets… Read more »